Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial-Reference-Cited by-同舟云学术

Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial

Published:2022-12 Issue:5 Volume:114 Page:856-861
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Baker Sarah,Mou Benjamin,Jiang Will,Liu Mitchell,Bergman Alanah M.,Schellenberg Devin,Alexander Abraham S.,Carolan Hannah,Atrchian Siavash,Berrang Tanya,Bang Andrew,Chng Nick,Matthews Quinn,Tyldesley Scott,Olson Robert A.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference14 articles.

1. Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: An international survey of >1000 radiation oncologists;Lewis;Am J Clin Oncol,2017

2. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial;Palma;Lancet,2019

3. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis;Pitroda;Nat Commun,2018

4. Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: Translational correlatives from a mature randomized phase II trial;Tang;Int J Radiat Oncol Biol Phys,2020

5. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial;Palma;BMC Cancer,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-04

2. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET;BMC Cancer;2024-02-03

3. Predicting long‑term survival following involved site radiotherapy for oligometastases;Oncology Letters;2024-01-05

4. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial;Radiotherapy and Oncology;2023-05

5. PROshot: SABR for Oligometastases, SABR for Renal Cell Carcinoma, Glioblastoma Multiforme Reirradiation, and Esophageal Squamous Cell Carcinoma;Practical Radiation Oncology;2023-03